Kankana Bardhan
Kankana Bardhan
Harvard Medical School
Verified email at mgh.harvard.edu
TitleCited byYear
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
N Patsoukis, K Bardhan, P Chatterjee, D Sari, B Liu, LN Bell, ED Karoly, ...
Nature communications 6, 6692, 2015
3102015
Epigenetics and colorectal cancer pathogenesis
K Bardhan, K Liu
Cancers 5 (2), 676-713, 2013
1812013
The PD1: PD-L1/2 pathway from discovery to clinical implementation
K Bardhan, T Anagnostou, VA Boussiotis
Frontiers in immunology 7, 550, 2016
1302016
NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression
F Liu, K Bardhan, D Yang, M Thangaraju, V Ganapathy, JL Waller, ...
Journal of Biological Chemistry 287 (30), 25530-25540, 2012
1052012
Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo
D Yang, CM Torres, K Bardhan, M Zimmerman, TL McGaha, K Liu
The Journal of Immunology 188 (9), 4441-4449, 2012
792012
Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer
X Hu, K Bardhan, AV Paschall, D Yang, JL Waller, MA Park, ...
Journal of Biological Chemistry 288 (26), 19103-19115, 2013
412013
GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology
H Liu, L Huang, J Bradley, K Liu, K Bardhan, D Ron, AL Mellor, DH Munn, ...
Molecular and cellular biology 34 (3), 428-438, 2014
382014
Clinical significance of T cell metabolic reprogramming in cancer
C Herbel, N Patsoukis, K Bardhan, P Seth, JD Weaver, VA Boussiotis
Clinical and translational medicine 5 (1), 29, 2016
362016
IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation
AV Paschall, R Zhang, CF Qi, K Bardhan, L Peng, G Lu, J Yang, M Merad, ...
The Journal of Immunology 194 (5), 2369-2379, 2015
322015
Corrigendum: Regulation of T Cell Differentiation and Function by EZH2
BVA Karantanos T, Christofides A, Bardhan K, Li L
front immunol 7, 172, 2016
252016
Lymphotoxin β receptor mediates caspase-dependent tumor cell apoptosis in vitro and tumor suppression in vivo despite induction of …
X Hu, MA Zimmerman, K Bardhan, D Yang, JL Waller, GB Liles, JR Lee, ...
Carcinogenesis 34 (5), 1105-1114, 2013
252013
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
BVA Christofides A, Karantanos T, Bardhan K
oncotarget, 2016
232016
IFNγ Induces DNA Methylation–silenced GPR109A expression via pSTAT1/p300 and H3K18 acetylation in colon cancer
K Bardhan, AV Paschall, D Yang, MR Chen, PS Simon, YD Bhutia, ...
Cancer immunology research 3 (7), 795-805, 2015
232015
The role of metabolic reprogramming in T cell fate and function
N Patsoukis, K Bardhan, J Weaver, C Herbel, P Seth, L Li, VA Boussiotis
Current trends in immunology 17, 1, 2016
92016
PD-1 inhibits the TCR signaling cascade by sequestering SHP-2 phosphatase, preventing its translocation to lipid rafts and facilitating Csk-mediated inhibitory phosphorylation …
K Bardhan, N Patsoukis, J Weaver, G Freeman, L Li, VA Boussiotis
The Journal of Immunology 196 (1 Supplement), 128.15-128.15, 2016
62016
NF-κB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression
PS Simon, K Bardhan, MR Chen, AV Paschall, C Lu, RJ Bollag, FC Kong, ...
Oncotarget 7 (17), 23395, 2016
52016
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 6: 6692
N Patsoukis, K Bardhan, P Chatterjee, D Sari, B Liu, LN Bell, ED Karoly, ...
Immunity 38, 633-643, 2015
42015
The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression
N Patsoukis, K Bardhan, JD Weaver, D Sari, A Torres-Gomez, L Li, ...
Sci. Signal. 10 (493), eaam8298, 2017
32017
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
L Marcar, K Bardhan, L Gheorghiu, P Dinkelborg, H Pfäffle, Q Liu, ...
Cell Reports 27 (12), 3422-3432. e4, 2019
12019
Interaction of both SH2 domains of SHP-2 with a PD-1 homodimer is required for PD-1-mediated inhibition of T cell responses
N Patsoukis, A Council, A Berg, K Bardhan, J Weaver, KM Mahoney, ...
The Journal of Immunology 198 (1 Supplement), 124.11-124.11, 2017
12017
The system can't perform the operation now. Try again later.
Articles 1–20